Jeffrey Schlom

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 85

Top Topics

Monoclonal Antibody

Prostate Cancer

Top Venues

Journal for immunotherapy of cancer

Nature communications

Journal of experimental & clinical cancer research : CR

This page only lists publications with an associated author ORCID identifier.

Publications

Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9. PloS one 19 (3) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Yo-Ting Tsai, Jeffrey Schlom, Renee N Donahue
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Stephanie C Pitts, Jeffrey Schlom, Renee N Donahue
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9. PloS one 19 (3) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9. PloS one 19 (3) (2024)
Yo-Ting Tsai, Jeffrey Schlom, Renee N Donahue
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Stephanie C Pitts, Jeffrey Schlom, Renee N Donahue
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9. PloS one 19 (3) (2024)
Meghali Goswami, Nicole J Toney, Stephanie C Pitts, Carolina Celades, Jeffrey Schlom, Renee N Donahue
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours. Clinical and translational medicine 14 (8) (2024)
Yo-Ting Tsai, Jeffrey Schlom, Renee N Donahue
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Meghali Goswami, Nicole J Toney, Stephanie C Pitts, Carolina Celades, Jeffrey Schlom, Renee N Donahue
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours. Clinical and translational medicine 14 (8) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Stephanie C Pitts, Jeffrey Schlom, Renee N Donahue
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9. PloS one 19 (3) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Meghali Goswami, Nicole J Toney, Stephanie C Pitts, Carolina Celades, Jeffrey Schlom, Renee N Donahue
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours. Clinical and translational medicine 14 (8) (2024)
Grace Lui, Christine M Minnar, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R Gameiro
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies. Cells 12 (12) (2023)
Julius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K Pachynski, Theodore S Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee N Donahue, Yo-Ting Tsai, XiaoZhe Wang, Yulia Vugmeyster, Frank Beier, Joerg Seebeck, Andreas Schroeder, Sarah Chennoufi, James L Gulley
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. Journal for immunotherapy of cancer 11 (5) (2023)
Scott M Norberg, Ke Bai, Cem Sievers, Yvette Robbins, Jay Friedman, Xinping Yang, Meg Kenyon, Elizabeth Ward, Jeffrey Schlom, James L Gulley, Amy Lankford, Roshanak Semnani, Helen Sabzevari, Douglas E Brough, Clint T Allen
The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis. Science translational medicine 15 (719) (2023)
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M Geynisman, Matthew Zibelman, Tina Mayer, Julius Strauss, Gang Chen, Myrna Rauckhorst, Sheri McMahon, Anna Couvillon, Seth Steinberg, William D Figg, William L Dahut, Jeffrey Schlom, James L Gulley
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The oncologist (2023)
Nicole J Toney, Jeffrey Schlom, Renee N Donahue
Phosphoflow cytometry to assess cytokine signaling pathways in peripheral immune cells: potential for inferring immune cell function and treatment response in patients with solid tumors. Journal of experimental & clinical cancer research : CR 42 (1) (2023)
S Elizabeth Franks, Ginette S Santiago-Sanchez, Kellsye P Fabian, Kristen Solocinski, Paul L Chariou, Duane H Hamilton, Joshua T Kowalczyk, Michelle R Padget, Sofia R Gameiro, Jeffrey Schlom, James W Hodge
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12. Cancer immunology, immunotherapy : CII (2023)
Grace Lui, Christine M Minnar, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R Gameiro
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies. Cells 12 (12) (2023)
Margaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss, Ravi A Madan, Fatima H Karzai, Marijo Bilusic, Jason Mark Redman, Houssein Abdul Sater, Charalampos S Floudas, Nicole J Toney, Renee N Donahue, Caroline Jochems, Jennifer L Marté, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa M Cordes, Jeffrey Schlom, James L Gulley
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. The oncologist (2023)
Madeline Dahut, Kristen Fousek, Lucas A Horn, Shantel Angstadt, Haiyan Qin, Duane H Hamilton, Jeffrey Schlom, Claudia Palena
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis. Journal for immunotherapy of cancer 11 (9) (2023)
Grace Lui, Christine M Minnar, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R Gameiro
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies. Cells 12 (12) (2023)
Maria Del Mar Maldonado, Jeffrey Schlom, Duane H Hamilton
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment. Cancer immunology, immunotherapy : CII (2023)
Jonathan Hsu, Renee N Donahue, Madan Katragadda, Jessica Lowry, Wei Huang, Karunya Srinivasan, Gurkan Guntas, Jian Tang, Roya Servattalab, Jacques Moisan, Yo-Ting Tsai, Allart Stoop, Sangeetha Palakurthi, Raj Chopra, Ke Liu, E John Wherry, Zhen Su, James L Gulley, Andrew Bayliffe, Jeffrey Schlom
A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Science translational medicine 15 (724) (2023)
Marijo Bilusic, Nicole J Toney, Renee N Donahue, Susan Wroblewski, Matthew Zibelman, Pooja Ghatalia, Eric A Ross, Fatima Karzai, Ravi A Madan, William L Dahut, James L Gulley, Jeffrey Schlom, Elizabeth R Plimack, Daniel M Geynisman
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate cancer and prostatic diseases 25 (4) (2022)
Yo-Ting Tsai, Julius Strauss, Nicole J Toney, Caroline Jochems, David J Venzon, James L Gulley, Jeffrey Schlom, Renee N Donahue
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. Journal for immunotherapy of cancer 10 (4) (2022)
Christine M Minnar, Paul L Chariou, Lucas A Horn, Kristin C Hicks, Claudia Palena, Jeffrey Schlom, Sofia R Gameiro
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. Journal for immunotherapy of cancer 10 (6) (2022)
Benjamin Wolfson, Michelle R Padget, Jeffrey Schlom, James W Hodge
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. Journal for immunotherapy of cancer 9 (7) (2022)
Peter Joseph DeMaria, Katherine Lee-Wisdom, Renee N Donahue, Ravi A Madan, Fatima Karzai, Angie Schwab, Claudia Palena, Caroline Jochems, Charalampos S Floudas, Julius Strauss, Jennifer L Marté, Jason Mark Redman, Eva Dombi, Brigitte Widemann, Borys Korchin, Tatiana Adams, Cesar Pico-Navarro, Christopher Heery, Jeffrey Schlom, James L Gulley, Marijo Bilusic
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. Journal for immunotherapy of cancer 9 (9) (2022)
Jason Mark Redman, Yo-Ting Tsai, Benjamin A Weinberg, Renee N Donahue, Shruti U Gandhy, Margaret E Gatti-Mays, Houssein Abdul Sater, Marijo Bilusic, Lisa M Cordes, Seth M Steinberg, Jennifer L Marte, Caroline Jochems, Sunnie S Kim, John L Marshall, Sheri McMahon, Erica Redmond, Jeffrey Schlom, James L Gulley, Julius Strauss
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. The oncologist 27 (3) (2022)
Cristina Mullenix, Madison Ballman, Haobin Chen, Shannon Swift, Meredith J McAdams, Yo-Ting Tsai, Renee N Donahue, Trina Poretta, Sarthak Gupta, Patrick J Loehrer, Jeffrey Schlom, James L Gulley, Arun Rajan
Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors. The oncologist 27 (4) (2022)
Yvette Robbins, Jay Friedman, Paul E Clavijo, Cem Sievers, Ke Bai, Renee N Donahue, Jeffrey Schlom, Andrew Sinkoe, Christian S Hinrichs, Clint T Allen, Houssein Abdul Sater, James L Gulley, Scott M Norberg
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. Journal for immunotherapy of cancer 9 (8) (2022)
Sofia R Gameiro, Julius Strauss, James L Gulley, Jeffrey Schlom
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status. Experimental biology and medicine (Maywood, N.J.) 247 (13) (2022)
Maxwell Y Lee, Simon Metenou, Douglas E Brough, Helen Sabzevari, Ke Bai, Caroline Jochems, Jeffrey Schlom, Clint T Allen
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. NPJ vaccines 6 (1) (2021)
Marijo Bilusic, Sheri McMahon, Ravi A Madan, Fatima Karzai, Yo-Ting Tsai, Renee N Donahue, Claudia Palena, Caroline Jochems, Jennifer L Marté, Charalampos S Floudas, Julius Strauss, Jason Redman, Houssein Abdul Sater, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James L Gulley
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer 9 (3) (2021)
John W Greiner, Y Maurice Morillon, Jeffrey Schlom
NHS-IL12, a Tumor-Targeting Immunocytokine. ImmunoTargets and therapy 10 (2021)
Ravi A Madan, Fatima Karzai, Renee N Donahue, Munjid Al-Harthy, Marijo Bilusic, Inger I Rosner, Harpreet Singh, Philip M Arlen, Marc R Theoret, Jennifer L Marté, Lisa M Cordes, Anna Couvillon, Amy Hankin, Moniquea Williams, Helen Owens, Sarah E Lochrin, Cindy H Chau, Seth Steinberg, William Douglas Figg, William Dahut, Jeffrey Schlom, James L Gulley
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. Journal for immunotherapy of cancer 9 (3) (2021)
Maxwell Y Lee, Yvette Robbins, Cem Sievers, Jay Friedman, Houssein Abdul Sater, Paul E Clavijo, Nancy Judd, Edward Tsong, Chris Silvin, Patrick Soon-Shiong, Michelle R Padget, Jeffrey Schlom, James Hodge, Christian Hinrichs, Clint T Allen
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. Journal for immunotherapy of cancer 9 (3) (2021)
Julius Strauss, Margaret E Gatti-Mays, Byoung Chul Cho, Andrew Hill, Sébastien Salas, Edward McClay, Jason M Redman, Houssein Abdul Sater, Renee N Donahue, Caroline Jochems, Elizabeth Lamping, Andrea Burmeister, Jennifer L Marté, Lisa M Cordes, Marijo Bilusic, Fatima Karzai, Laureen S Ojalvo, Genevieve Jehl, P Alexander Rolfe, Christian S Hinrichs, Ravi A Madan, Jeffrey Schlom, James L Gulley
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. Journal for immunotherapy of cancer 8 (2) (2021)
Claire Smalley Rumfield, Samuel T Pellom, Y Maurice Morillon Ii, Jeffrey Schlom, Caroline Jochems
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. Journal for immunotherapy of cancer 8 (1) (2021)
Kellsye P Fabian, Michelle R Padget, Renee N Donahue, Kristen Solocinski, Yvette Robbins, Clint T Allen, John H Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. Journal for immunotherapy of cancer 8 (1) (2021)
Kellsye P Fabian, Michelle R Padget, Rika Fujii, Jeffrey Schlom, James W Hodge
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. Journal for immunotherapy of cancer 9 (2) (2021)
Lucas A Horn, Kristen Fousek, Duane H Hamilton, James W Hodge, John A Zebala, Dean Y Maeda, Jeffrey Schlom, Claudia Palena
Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. Cancers 13 (5) (2021)
Kristen Solocinski, Michelle R Padget, Kellsye P Fabian, Benjamin Wolfson, Fabiola Cecchi, Todd Hembrough, Stephen C Benz, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge
Overcoming hypoxia-induced functional suppression of NK cells. Journal for immunotherapy of cancer 8 (1) (2021)
Karin M Knudson, Kristin C Hicks, Yohei Ozawa, Jeffrey Schlom, Sofia R Gameiro
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Journal for immunotherapy of cancer 8 (1) (2021)
Peter Joseph DeMaria, Marijo Bilusic, Deric M Park, Christopher R Heery, Renee N Donahue, Ravi A Madan, Mohammad Hadi Bagheri, Julius Strauss, Victoria Shen, Jennifer L Marté, Seth M Steinberg, Jeffrey Schlom, Mark R Gilbert, James L Gulley
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. The oncologist 26 (5) (2021)
Kristin C Hicks, Paul L Chariou, Yohei Ozawa, Christine M Minnar, Karin M Knudson, Thomas J Meyer, Jing Bian, Margaret Cam, Jeffrey Schlom, Sofia R Gameiro
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. Nature communications 12 (1) (2021)
Yohei Ozawa, Kristin C Hicks, Christine M Minnar, Karin M Knudson, Jeffrey Schlom, Sofia R Gameiro
Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. Oncoimmunology 10 (1) (2021)
Danielle M Pastor, Jeffrey Schlom
Immunology of Lynch Syndrome. Current oncology reports 23 (8) (2021)
Renee N Donahue, Jennifer L Marté, Meghali Goswami, Nicole J Toney, Yo-Ting Tsai, James L Gulley, Jeffrey Schlom
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. Journal for immunotherapy of cancer 9 (3) (2021)
Karin L Lee, Jeffrey Schlom, Duane H Hamilton
Combination therapies utilizing neoepitope-targeted vaccines. Cancer immunology, immunotherapy : CII 70 (4) (2020)
Claire Smalley Rumfield, Nicholas Roller, Samuel Troy Pellom, Jeffrey Schlom, Caroline Jochems
Therapeutic Vaccines for HPV-Associated Malignancies. ImmunoTargets and therapy 9 (2020)
Claire Smalley Rumfield, Jeffrey Schlom, Caroline Jochems
Combination Therapies for HPV-Associated Malignancies. Journal of clinical & cellular immunology 12 (1) (2020)
Kellsye P Fabian, Anthony S Malamas, Michelle R Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii, Houssein Abdul Sater, Jeffrey Schlom, James W Hodge
Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. Cancer immunology research 9 (2) (2020)
Karin M Knudson, James W Hodge, Jeffrey Schlom, Sofia R Gameiro
Rationale for IL-15 superagonists in cancer immunotherapy. Expert opinion on biological therapy 20 (7) (2020)
Jennifer L Marté, Nicole J Toney, Lisa M Cordes, Jeffrey Schlom, Renee N Donahue, James L Gulley
Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. Journal for immunotherapy of cancer 8 (2) (2020)
Sarah Greene, Yvette Robbins, Wojciech K Mydlarz, Angel P Huynh, Nicole C Schmitt, Jay Friedman, Lucas A Horn, Claudia Palena, Jeffrey Schlom, Dean Y Maeda, John A Zebala, Paul E Clavijo, Clint Allen
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6) (2019)
Karin M Knudson, Kristin C Hicks, Sarah Alter, Jeffrey Schlom, Sofia R Gameiro
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. Journal for immunotherapy of cancer 7 (1) (2019)
Kristin C Hicks, Karin M Knudson, Karin L Lee, Duane H Hamilton, James W Hodge, William Douglas Figg, Peter Ordentlich, Frank R Jones, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R Gameiro
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (3) (2019)
Karin L Lee, Stephen Charles Benz, Kristin C Hicks, Andrew Nguyen, Sofia R Gameiro, Claudia Palena, John Z Sanborn, Zhen Su, Peter Ordentlich, Lars Rohlin, John H Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Kayvan Niazi, Jeffrey Schlom, Duane H Hamilton
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. Cancer immunology research 7 (8) (2019)
Y Maurice Morillon, Zhen Su, Jeffrey Schlom, John W Greiner
Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. Journal for immunotherapy of cancer 7 (1) (2019)
Margaret E Gatti-Mays, Julius Strauss, Renee N Donahue, Claudia Palena, Jaydira Del Rivero, Jason Mark Redman, Ravi A Madan, Jennifer L Marté, Lisa M Cordes, Elizabeth Lamping, Alanvin Orpia, Andrea Burmeister, Eva Wagner, Cesar Pico Navarro, Christopher R Heery, Jeffrey Schlom, James L Gulley
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (16) (2019)
Caroline Jochems, Sarah R Tritsch, Karin M Knudson, Sofia R Gameiro, Claire Smalley Rumfield, Samuel T Pellom, Y Maurice Morillon, Robby Newman, Warren Marcus, Christopher Szeto, Shahrooz Rabizadeh, Hing C Wong, Patrick Soon-Shiong, Jeffrey Schlom
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. Oncoimmunology 8 (2) (2018)
Caroline Jochems, James W Hodge, Massimo Fantini, Kwong Y Tsang, Amanda J Vandeveer, James L Gulley, Jeffrey Schlom
ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. International journal of cancer 141 (3) (2017)
Renee N Donahue, Lauren M Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A Madan, Christopher R Heery, James L Gulley, Jeffrey Schlom
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. Journal for immunotherapy of cancer 5 (2017)